In the years following FDA approval of direct-to-consumer, genetic-health-risk/DTCGHR testing, millions of people in the US have sent their DNA to companies to receive personal genome health risk information without physician or other learned medical professional involvement. In Personal Genome Medicine, Michael J. Malinowski examines the ethical, legal, and social implications of this development. Drawing from the past and present of medicine in the US, Malinowski applies law, policy, public and private sector practices, and governing norms to analyze the commercial personal genome sequencing and testing sectors and to assess their impact on the future of US medicine. Written in relatable and accessible language, the book also proposes regulatory reforms for government and medical professionals that will enable technological advancements while maintaining personal and public health standards.

An ever increasing number of drugs are known to cause gastrointestinal injury. The histological features are often non-specific and a single drug can induce many different patterns, necessitating close collaboration between pathologists and clinicians to reach a correct diagnosis. However, there may be some histological clues that are helpful in the diagnosis of drug-induced injury.